About Us

We leverage our proprietary ex vivo 3D cell culture technology platforms to accurately model and predict response to approved and investigational cancer drugs targeting a spectrum of solid tumors.

Drug Development Services:  We work with leading biopharmaceutical companies to unlock response dynamics (ex vivo efficacy) for their investigational cancer drug candidates in preclinical testing and subsequent clinical trials.

Clinical Testing Services (CLIA-certified laboratory):  In 2019 we published of our assay’s analytical validation and clinical evidence of its predictive performance.  Currently we are further validating drug response-predictive clinical assays as well as undertaking investigator-initiated studies in ovarian cancer, high-grade glioma, breast cancer and rare tumors.

Our Science

Our ex vivo 3D cell culture platforms enable us to utilize live cancer cells from surgical or biopsy tissue specimens in order to create a patient-specific in vivo-like tumor and immune microenvironment, outside the body, in which to accurately model and assess response (ex vivo efficacy) to investigational and approved cancer therapies.

Ex vivo 3D cell culture is unique in that it maximizes patient relevance in the in vitro assessment of drug-on-tumor cell interaction prior to in vivo therapy administration.

3dcellculture

We are constantly expanding the scientific boundaries of ex vivo 3D cell culture capability. Our evidence base spans most solid tumor types and cancer drug classes, offering unparalleled predictive utility in the clinic and in the drug development laboratory.

kiyatecpipeline

Key Citations

3D Cell Culture Platform Validation

  • Redefining Personalized Medicine by Drug Response Profiling of Patient-Derived Spheroids

Breast Cancer

  • Complex, Patient-Derived, Multi-Cell Type, 3D Models of Breast Cancer for Personalized Prediction of Therapeutic Response
  • 3D Modeling of Immune Cell Interactions in Breast Cancer and Prediction of Immunotherapy Response
  • Perfused 3D Tri-Culture Breast Cancer Microtumors for Accurate Prediction of Drug Response

Brain Cancer

  • Prospective Validation of an Ex Vivo 3D Assay for Prediction of Temozolomide Response in Glioblastoma
  • Ex Vivo Models of Glioblastoma: A Comparison of 3D Tissues and Patient-Derived Xenografts to Clinical Response
  • Profiling Patient-Specific Glioblastoma Drug Response In Vitro Using Complex 3D Microtumors
  • Development of an in Vitro 3D Glioblastoma Model System for Patient-Specific Drug Response Profiling
  • A Complex 3D Model of Glioblastoma for Patient-Specific Drug Response Profiling

Ex Vivo Testing of Patient-Derived Xenografts (PDX)

  • Establishment and characterization of paired palbociclib-sensitive and resistant luminal A breast PDX models
  • Enhancing Drug Discovery & Development Throughput Without Sacrificing Predictivity: ex vivo 3D Drug Response Profiling Using PDX

Immuno-Oncology

  • Multifaceted functional assessment of checkpoint inhibitor efficacy using 3D tumor spheroids
  • PARP inhibition in combination with pembrolizumab enhances cytotoxicity in ovarian cancer patient-derived 3D spheroids
  • Predicting Patient Response to Checkpoint Blockade Therapy Using In Vitro 3D Culture
  • Predicting Patient Response to Immuno-Oncology Agents In Vitro Using 3D Cultures
  • 3D Tissue Models to Predict Patient-Specific Responses to immuno-Oncology Agents
  • Complex, 3D Tissues for Modeling the Immune Response in Cancer and Predicting the Activity of Immunotherapies

In Vitro Platelets

  • Closed-Loop Bioreactor for In Vitro Platelet Production from Hematopoietic Stem Cells

Ovarian Cancer

  • Prospective Validation of an Ex Vivo, Patient-Derived 3D Spheroid Model for Response Predictions in Newly Diagnosed Ovarian Cancer

Rare Tumors

  • The Perfused 3DKUBE™ Rare Tumor Assay Models In Vivo Drug Response
  • Paired Isolation and Expansion of CSC and CTC from Primary Small Cell Lung Cancer Patient Tissue and Blood Using the 3DKUBE® Bioreactor Platform
  • Marker Free Isolation and Expansion of Cancer Stem Cells from Small Cell Lung Cancer

For Access to Citations

News

University of Arkansas for Medical Sciences Joins KIYATEC Clinical Study of Test to Predict Pre-Treatment, Patient-Specific Response to Ovarian Cancer Drugs
June 25, 2020

Cancer Diagnostics Innovator KIYATEC Advancing Functional Ex Vivo 3D Cell Culture Models that Reveal Response Dynamics to Immuno-Oncology Drugs
June 22, 2020

Cancer Diagnostics Innovator KIYATEC Adds Clinical and Reimbursement Experience to Board as Clinical Testing Validation Progresses
May 4, 2020

Cancer Diagnostics Innovator KIYATEC Expands Services to Help Relieve COVID-19 Testing Bottleneck
April 1, 2020

VA Portland Health Care System Joins KIYATEC Clinical Study of Test to Predict Pre-Treatment, Patient-Specific Response to Glioblastoma Drugs
March 2, 2020

KIYATEC Secures Investment from Life Sciences Venture Fund Esperante to Fuel Clinical Assay Validation Efforts
January 8, 2020

CarThera and KIYATEC Collaborate in Effort to Bring Personalized Medicine to Patients Stricken by Brain Cancer
November 18, 2019

KIYATEC To Present Immuno-Oncology Response Characterization at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 5, 2019

KIYATEC Announces Addition of Capital Health as Clinical Site in Trial to Predict GBM Patient-Specific Response to Cancer Drugs Prior to Treatment
August 13, 2019

KIYATEC Assay Hits the Mark in Study to Predict Patient Response to First Line Ovarian Cancer Drugs
August 1, 2019

KIYATEC Announces $3 Million Initial Closing of Series B2 Preferred Stock Financing and New Investor LabCorp
May 1, 2019

KIYATEC Selected for University Innovation and Entrepreneurship Startup Showcase on Capitol Hill
April 10, 2019

KIYATEC to Present Data on Advanced Ex Vivo 3D Cell Culture Technology to Aid Cancer Patient Care and Drug Development at AACR 2019
March 28, 2019

Inova Health System and Roswell Park Comprehensive Cancer Center Join KIYATEC Clinical Trial to Predict Patient Response to Cancer Drugs Prior to Treatment
March 15, 2019

KIYATEC Adds Oregon Health & Science University to Study to Predict Response to Cancer Therapy Prior to Treatment
February 6, 2019

KIYATEC Announces Enrollment of First Patients in Clinical Trial to Predict Personalized Response to Oncology Drugs Prior to Treatment
June 20, 2018

KIYATEC Strengthens Leadership Team with Appointment of Vice Presidents of Clinical Affairs and Commercial Operations
May 29, 2018

Team

Executive Team

Matthew R. Gevaert, Ph.D. : CEO & Co-founder

Dr. Matthew (Matt) Gevaert is the Chief Executive Officer and a co-founder of KIYATEC, Inc. Under Matt’s leadership and support of an incredible team, KIYATEC has earned national recognition for its progress towards accurately modeling and predicting cancer patient response to drug therapies prior to treatment. Based on 3D cell culture technology, the company has pioneered a novel “in-hospital startup” model to solve intrinsically complex healthcare problems for the betterment of cancer patients, developing elegant solutions that will ultimately work both for the hospital “down the hall” as well as across the continent. Through a dedicated focus on direct relevance to cancer patients, KIYATEC has successfully attracted multiple rounds of private sector investment, more than $5M of competitively awarded federal funding including contracts from the National Cancer Institute, prestigious clinical collaborators at leading national cancer institutions and relationships with premier biopharmaceutical companies developing the cancer therapies of the future.

Matt is a graduate of the University of Waterloo (B.Sc., Chemistry) and of Clemson University (M.S. and Ph.D., Bioengineering). He serves on a number of professional and community boards and occasionally teaches an MBA graduate course in technology entrepreneurship for professional business students.
Lillia M. Holmes, M.S. : Chief Operations Officer

Lillia Holmes is Chief Operations Officer overseeing KIYATEC’s operations and regulatory compliance. Prior to KIYATEC, Lillia gained experience in operational and financial management and furthered her regulatory affairs expertise as the Director of Cellular Therapy at The Blood Connection, Inc. where she managed the processing facility for bone marrow transplants and served as the Technical Supervisor for CLIA high complexity testing. Her interest in operational management and cellular therapy stemmed from translating oncology research to clinical therapies during her time as a Research Associate for the Greenville Hospital System Oncology Research Institute. Since that time, Lillia has continued to develop her knowledge of FDA, CLIA, FACT and AABB regulations and standards and has successfully translated that knowledge to operational improvements for biotechnology organizations as well as both research and clinical laboratories. Lillia is a Greenville, SC native and attended the University of South Carolina at Spartanburg where she graduated cum laude with a B.S. in Biology. She then furthered her education at East Tennessee State, Quillen College of Medicine by earning a M.S. in Biomedical Sciences. Her love for Greenville led her back home where she has been instrumental in oncology research and cellular therapy manufacturing. Passionate about oncology and blood donation, Lillia brings a unique perspective to KIYATEC’s mission.
Tessa DesRochers, Ph.D. : Chief Scientific Officer

Dr. Tessa DesRochers is the Chief Scientific Officer responsible for managing all research and development within KIYATEC, including all government contracts and grants, external collaborations, and internal preclinical and clinical assay development. Before joining the company, Tessa was in the Department of Biomedical Engineering at Tufts University where she developed bioengineered 3D models of human kidney tissue and breast cancer with applications in the areas of nephrotoxicology, disease modeling, and infectious disease. She has published numerous peer-reviewed articles in the area of tissue engineering and disease applications, has presented a number of abstracts at multiple scientific meetings, and serves as an ad hoc reviewer for several peer-reviewed journals. As a “military brat”, Tessa grew up in numerous locations, including California, England, and Ohio before her family settled in New Hampshire. She attended the University of New Hampshire where she graduated cum laude with a B.S. in Biochemistry. She received her PhD from Tufts University’s Sackler School of Graduate Biomedical Sciences in Cell, Molecular, and Developmental Biology where her thesis focused upon epigenetic gene regulation in a 3D model of human skin. Her postdoctoral training included a year at Children’s Hospital in Boston and subsequent training in the lab of Dr. David Kaplan at Tufts University. Tessa is committed to the development of 3D tissues as better models of human development and disease.
Wes Carr, CPA : Chief Financial Officer

Wes Carr, CPA, is a cofounder and managing partner at Ethan Rivers, LLC – a management accounting and business operations firm in Greenville, South Carolina. Wes began his public accounting career with Ernst & Young, LLP and then went on to gain industry experience within manufacturing, tech, real estate, service, and non-profit organizations. Wes currently serves a number of businesses as fractional CFO. He holds a bachelor’s degree in accounting from Bob Jones University and an MBA from Clemson University.
Cecile Rose T. Vibat, Ph.D., PMP: Senior Director, Clinical Affairs

Dr. Cecile Rose Vibat is Senior Director, Clinical Affairs and is responsible for managing KIYATEC’s clinical development programs. She has an extensive background in translational science, as well as leading research and development teams in molecular diagnostics with emphasis in molecular biology, functional genomics and biochemistry. Prior to joining KIYATEC, Cecile Rose served as Senior Director of Clinical and Translational Affairs at Biocept, Inc., where she oversaw active clinical studies in liquid biopsy and provided key scientific and clinical input for cross-functional areas within the company. She was also Senior Director of Translational Science and Clinical Affairs at Trovagene, Inc., where she led clinical study programs to evaluate the potential clinical utility of non-invasive urine-based technologies in oncology and infectious disease. Cecile Rose has authored numerous peer-reviewed publications in addition to the submission of patent applications. Cecile Rose is a graduate of the University of California, Berkeley, where she received her Bachelors in Biochemistry. She received her Ph.D. in Biochemistry from the University of Illinois at Urbana-Champaign and was a postdoctoral fellow at the University of California, Davis. Cecile Rose is a certified Project Management Professional (PMP).

Board of Directors

Robert Silverman, Chairman

Mr. Silverman is the former CEO of mtm laboratories AG, an in-vitro diagnostics company which developed and commercialized a portfolio of products using its patent protected biomarkers for early detection and diagnosis of cervical cancer. He was instrumental in building this company into a global, fully integrated business, with a strong foundation of significant clinical utility and commercial momentum. Mr. Silverman successfully negotiated the purchase of mtm by Roche Diagnostics in August 2011 for a total deal value of $270 Million and then facilitated the integration of mtm into Roche. Prior to mtm laboratories, Mr. Silverman was the Senior Vice-President of Worldwide Commercial Operations for Viacell, a company focused on developing stem cell therapies and cord blood banking. Before this, he spent 6 years with Cytyc Corporation. During his tenure at Cytyc, he served as the Vice President of Marketing and the Vice President of International, and was integral in launching and establishing the core technology (the ThinPrep Pap Test) into the standard of care for cervical cancer screening. Previous positions include Vice-President of Marketing for Pasteur Merieux Connaught, Director of New Product Development for Abbott Laboratories Pharmaceutical Products Division and Management Consultant with Bain and Company. He earned his Master’s degree in Marketing and Finance from Northwestern’s Kellogg Graduate School of Management and received his Bachelor of Science degree in Pharmacy from the University of Michigan. Mr. Silverman currently works with several companies in a Board and Advisory capacity.
Christopher Brotherton
Christopher is the Corporate Vice President of Ortec, Inc., a South Carolina company offering custom manufacturing services for pharmaceutical, medical device and combination products. Prior to joining Ortec, Christopher was with Nalco Company where he held several positions in product marketing, international marketing, and strategic mergers & acquisitions. He holds a bachelors degree in chemistry from Clemson University and an MBA from Wake Forest University.
Matthew R. Gevaert, Ph.D., CEO & Co-founder

Dr. Matthew (Matt) Gevaert is the Chief Executive Officer and a co-founder of KIYATEC, Inc. Under Matt’s leadership and support of an incredible team, KIYATEC has earned national recognition for its progress towards accurately modeling and predicting cancer patient response to drug therapies prior to treatment. Based on 3D cell culture technology, the company has pioneered a novel “in-hospital startup” model to solve intrinsically complex healthcare problems for the betterment of cancer patients, developing elegant solutions that will ultimately work both for the hospital “down the hall” as well as across the continent. Through a dedicated focus on direct relevance to cancer patients, KIYATEC has successfully attracted multiple rounds of private sector investment, more than $5M of competitively awarded federal funding including contracts from the National Cancer Institute, prestigious clinical collaborators at leading national cancer institutions and relationships with premier biopharmaceutical companies developing the cancer therapies of the future.

Matt is a graduate of the University of Waterloo (B.Sc., Chemistry) and of Clemson University (M.S. and Ph.D., Bioengineering). He serves on a number of professional and community boards and occasionally teaches an MBA graduate course in technology entrepreneurship for professional business students.
Bruce Nash, MD, MBA

Dr. Nash brings over 30 years of executive-level healthcare experience in the managed care, hospital and medical group practice settings.  Currently, he serves as Chief Physician Executive and Senior Vice President at Blue Cross Blue Shield of Massachusetts, one of the nation’s leading health insurance plans.  During his career, Dr. Nash has held executive leadership positions in both managed care (Kaiser Permanente, Capital District Physicians’ Health Plan) and healthcare (Northern Berkshire Health System, North Adams Regional Hospital) organizations.  Dr. Nash serves on the boards of the Blue Cross Blue Shield Foundation and the Network for Excellence in Health Innovation (NEHI), while also serving on the Board of Strategic Advisors at the Excel Venture Management Fund and the Clinical Advisory Group at the Blue Venture Fund.  He is a board-certified physician who completed his residency training at Duke University. Bruce earned his MBA in Health Sector Management from Duke University's Fuqua School of Business.
Gregory F. Zaic

Greg has over 27 years of venture capital investment experience, having played a leadership role in the management of a number of venture capital funds. He currently represents Nexus on the Boards of Aethon, Kiyatec and Zipit Wireless. Greg also represented Nexus as a director of Sabal Medical and Cutanea Life Sciences until he negotiated their sale to a European and Asian acquirer respectively. In the past, he has been an active Board member of both public and private corporations, providing assistance and guidance on issues associated with business strategy, corporate expansion, organizational development, and becoming successful publicly traded companies. Selected investments include Biodel (novel insulin formulation, IPO), PerSeptive Biosystems (protein separation systems, acquired by Perkin Elmer) and Infusion Systems (disposable IV pump, acquired by Baxter). Prior to joining Nexus, Greg was a general partner of Prince Ventures, a healthcare- focused, venture capital partnership. During the 1980s, Greg was Vice President and Special Limited Partner of the Vista Group where he worked closely with Ed Snape, the leader of Vista’s health care practice, and Bob Fleming, Vista’s IT partner. From 1972 until 1979, Greg was an executive with Baxter Laboratories. His three member team was responsible for bringing CAPD (Continuous Ambulatory Peritoneal Dialysis) into Baxter, where it became the second-most profitable product line in the company, then accounting for approximately 20% of Baxter’s total profits. Greg received a BS in aerospace and mechanical engineering from Princeton University; an MS in mechanical engineering the Massachusetts Institute of Technology (MIT); and an MS from MIT’s Sloan School of Management.

Contact

We leverage our proprietary ex vivo 3D cell culture technology platforms to accurately model and predict response to approved and investigational cancer drugs targeting a spectrum of solid tumors.

Drug Development Services:  We work with leading biopharmaceutical companies to unlock response dynamics (ex vivo efficacy) for their investigational cancer drug candidates in preclinical testing and subsequent clinical trials.

Clinical Testing Services (CLIA-certified laboratory):  In 2019 we published of our assay’s analytical validation and clinical evidence of its predictive performance.  Currently we are further validating drug response-predictive clinical assays as well as undertaking investigator-initiated studies in ovarian cancer, high-grade glioma, breast cancer and rare tumors.

KIYATEC
900-B West Faris Road
Greenville, SC  29605  USA
Tel:  864-502-2013
Email us:  customer.service@kiyatec.com
http://kiyatec.com/
https://www.linkedin.com/company/kiyatec-inc-/
https://twitter.com/KIYATEC
CLIA certification:  42D2130169